MDLinxThese 2 Existing Drugs May Boost Brain Health, Scientists Say

A phase I safety trial tested empagliflozin and intranasal insulin in 47 adults with mild cognitive impairment, mild dementia, or preclinical Alzheimer’s markers. Both medications demonstrated favorable safety profiles while targeting metabolic dysfunction linked to Alzheimer’s progression. The study revealed preliminary efficacy signals warranting larger controlled trials.

🔬 Key Clinical Considerations

• Empagliflozin reduced cerebrospinal fluid tau levels and improved cerebral blood flow, cholesterol markers, and inflammatory biomarkers in participants with early-stage cognitive decline over four weeks.
• Intranasal insulin improved cognitive test scores for memory and executive function while enhancing white matter connectivity and memory-related cerebral blood flow on neuroimaging studies.
• The trial’s primary endpoint was safety assessment rather than efficacy; the 47-participant cohort lacked statistical power to detect significant between-group differences in cognitive outcomes.
• Combination therapy safety was established with no adverse effects reported when both medications were administered concurrently, supporting future investigation of synergistic metabolic targeting approaches.
• Metabolic dysfunction represents an emerging therapeutic target as both medications address insulin resistance, glucose dysregulation, and cellular energy metabolism implicated in Alzheimer’s pathophysiology.

🎯 Clinical Practice Impact

• Patient Communication: Discuss emerging metabolic approaches for patients with early cognitive decline, emphasizing investigational status while addressing questions about repurposing existing medications.
• Practice Integration: Monitor for larger trial results before changing clinical practice; consider metabolic optimization in at-risk patients through established diabetes management protocols.
• Risk Management: Document off-label medication requests appropriately; explain preliminary nature of evidence and FDA approval requirements for Alzheimer’s indications.
• Future Preparation: Anticipate patient inquiries about empagliflozin and intranasal insulin following media coverage of metabolic intervention strategies.

More on Alzheimer’s/Dementia